论文部分内容阅读
目的 评价IMVP - 1 6方案治疗复发和难治性非霍奇金淋巴瘤的疗效及毒性。方法 采用IMVP - 1 6方案治疗32例复发和难治性非霍奇金淋巴瘤,其中复发组1 8例,难治组1 4例。结果 32例中完全缓解CR 8例(2 5 .0 %) ,部分缓解PR 7例(2 1 .8%) ,总有效率为4 6 .8%。有效患者中位缓解时间6 .4个月。IMVP - 1 6方案治疗后中位生存时间8.3个月,1年总生存率34.1 %,2年总生存率1 9.7%。IMVP - 1 6方案的不良反应主要表现为骨髓抑制,1 0例患者发生了白细胞减少引起的发热,其中有1例发生了化疗相关性死亡。结论 IMVP - 1 6方案治疗复发和难治性非霍奇金淋巴瘤的疗效是肯定的,毒性反应可以耐受,然而此方案的结果并不十分令人满意,仍然需要探索更好的高效、低毒的治疗方案。
Objective To evaluate the efficacy and toxicity of IMVP - 1 6 in the treatment of relapsed and refractory non - Hodgkin ’s. Methods 32 patients with relapsed and refractory non - Hodgkin ’s lymphoma were treated with IMVP - 1 6 regimen, including 18 in the recurrent group and 14 in the refractory group. Results Among the 32 cases, CR was completely relieved in 8 cases (25.0%) and partial PR was relieved in 7 cases (21.8%) with a total effective rate of 46.8%. Effective patient median response time of 6.4 months. The median survival time after IMVP - 1 6 treatment was 8.3 months, the 1 - year overall survival rate was 34.1% and the 2 - year overall survival rate was 1 9.7%. Adverse reactions to IMVP-1 6 regimen were mainly myelosuppression, and 10 patients developed fever due to leucopenia. One patient had chemotherapy-related death. Conclusions The efficacy of IMVP - 1 6 regimen in the treatment of relapsed and refractory non - Hodgkin ’s lymphoma is affirmative and the toxicity response is tolerable. However, the results of this regimen are not very satisfactory. However, there is still a need to explore better, Low toxicity treatment options.